Physician

Ravi Shankar, MD

According to 2025 Medicare claims, Ravi Shankar, MD (NPI: 1861407421) practices radiation oncology in the Palm Bay-Melbourne-Titusville, FL market, with the plurality of this provider's patient population coming from Brevard, FL. This provider's primary affiliated billing organization is CANCER CARE CENTERS OF BREVARD INC (NPI: 1467551762; TIN: 593169766) and primary practice location at 32901-3119. Shankar is affiliated with the Primary Care Alliance, LLC (ACO ID: D0010), participating under the REACH model.

Shankar's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 620 traditional Medicare patients, billed 14,700 HCPCS/CPT codes, and received $1,538,970 in Medicare payments. The top billing code was G6015 (Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session). Part D data shows 374 prescription claims across 154 beneficiaries totaling $8,679 in drug costs, led by Pilocarpine Hcl (Pilocarpine Hcl). 2018 DME data shows 24 claims. Open Payments data shows 8 records totaling $189. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has changed little. Concurrently, Part D prescription costs have moved up and down with repeated peaks and valleys, starting at $8,365 and ending at $8,679. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	687	18,380	$1,346,028
2016	712	21,594	$1,594,412
2017	721	17,879	$1,477,814
2018	717	18,899	$1,601,823
2019	695	11,717	$1,421,624
2020	673	16,503	$1,527,916
2021	657	15,358	$1,418,225
2022	683	13,849	$1,541,459
2023	683	13,759	$1,558,966
2024	620	14,700	$1,538,970

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	90	234	$8,365
2016	111	276	$12,253
2017	114	323	$10,452
2018	90	196	$7,695
2019	104	316	$10,677
2020	129	311	$7,605
2021	124	288	$8,887
2022	114	262	$8,426
2023	151	363	$11,458
2024	154	374	$8,679

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	N/R	N/R
2016	N/R	N/R	N/R
2017	N/R	N/R	N/R
2018	N/R	24	$907
2019	N/R	N/R	N/R
2020	N/R	N/R	N/R
2021	N/R	N/R	N/R
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	N/R	N/R

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
G6015	Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session	178	1,617	$282
77263	Complex radiation therapy planning	137	146	$136
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	255	389	$71
G6002	Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy	203	1,492	$61
77300	Calculation of radiation therapy dose	133	528	$53

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Pilocarpine Hcl	Pilocarpine Hcl	39	2,340	$3,507
Tamsulosin Hcl	Tamsulosin Hcl	145	8,620	$1,436
Bicalutamide	Bicalutamide	31	547	$467
Dexamethasone	Dexamethasone	15	393	$433
Ssd	Silver Sulfadiazine	16	420	$224

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	8	$189	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Ravi Shankar, MD?

Tedicare shows public-source Medicare data for Ravi Shankar, MD (NPI 1861407421), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Ravi Shankar, MD have ACO affiliation data?

Ravi Shankar, MD is shown with ACO affiliation data for Primary Care Alliance, LLC (REACH, ACO ID D0010).

What billing organization is linked to Ravi Shankar, MD?

Ravi Shankar, MD is linked to CANCER CARE CENTERS OF BREVARD INC (billing NPI 1467551762) in the available physician profile data.

Does Ravi Shankar, MD have Open Payments data?

Ravi Shankar, MD has 8 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.